医学
食管癌
肿瘤科
新辅助治疗
内科学
化疗
随机对照试验
放化疗
放射治疗
癌症
乳腺癌
作者
Shaowu Jing,Jianjun Qin,Qing Liu,Chang Zhai,Yajing Wu,Yunjie Cheng,Brian G. Czito,Jun Wang
出处
期刊:Future Oncology
[Future Medicine]
日期:2019-07-04
卷期号:15 (20): 2413-2422
被引量:25
标识
DOI:10.2217/fon-2019-0024
摘要
Aim: To compare the clinical efficacy of neoadjuvant chemoradiotherapy (nCRT) and neoadjuvant chemotherapy (nCT) for esophageal cancer. Methods: Randomized controlled trials reporting on the comparison of nCRT and nCT for esophageal cancer were identified. Results: Three eligible randomized controlled trials were identified and included with a total of 375 patients (189 nCRT, 186 nCT). Outcomes showed that compared with nCT group, R0 resection and pathologic complete response (pCR) rates were significantly increased in nCRT group. However, no significant difference was seen in 3- and 5-year progression-free survival or 3- and 5-year overall survival. Conclusion: The addition of radiotherapy to neoadjuvant chemotherapy results in higher R0 resection rate and pCR rate, without significantly impacting survival.
科研通智能强力驱动
Strongly Powered by AbleSci AI